# Amino Acid Disorders: Phenylketonuria as a Paradigm

## Overview

Phenylketonuria (PKU) is the prototypical inborn error of metabolism and the model for newborn screening-based early intervention. It is caused by deficiency of phenylalanine hydroxylase (PAH), which converts phenylalanine (Phe) to tyrosine (Tyr). Inheritance is autosomal recessive with a carrier frequency of approximately 1 in 50 in European-descent populations and an incidence of roughly 1 in 10,000-15,000 in most populations (higher in Ireland and Turkey, lower in Finland and Japan). Without treatment, PKU causes severe intellectual disability, seizures, and behavioral abnormalities. With early dietary treatment, individuals with PKU can achieve normal cognitive outcomes.

## Biochemistry and Pathophysiology

### Phenylalanine Hydroxylase System

PAH converts L-phenylalanine to L-tyrosine in the liver, requiring tetrahydrobiopterin (BH4) as a cofactor along with molecular oxygen and iron. BH4 is regenerated by dihydropteridine reductase (DHPR) and synthesized by GTP cyclohydrolase I and 6-pyruvoyltetrahydropterin synthase. Deficiency of BH4 synthesis or regeneration causes "BH4-responsive" or "atypical" PKU, which is distinct from classic PAH deficiency.

### Metabolic Consequences of PAH Deficiency

PAH deficiency leads to accumulation of phenylalanine in blood and tissues, decreased tyrosine production (making tyrosine conditionally essential), and elevated transamination products (phenylpyruvate, phenyllactate, and phenylacetate -- the latter causing the characteristic "mousy" odor). Excess phenylalanine disrupts large neutral amino acid transport across the blood-brain barrier, neurotransmitter synthesis (dopamine, serotonin, norepinephrine), and myelin formation. Tyrosine deficiency reduces melanin production, explaining the fair skin and light hair seen in untreated PKU.

<image>Diagram of the phenylalanine hydroxylase reaction showing phenylalanine conversion to tyrosine, the role of BH4 cofactor, and the alternative transamination pathway producing phenylpyruvate and phenylacetate in PAH deficiency</image>

## Classification

### Classic PKU

Classic PKU involves less than 1% of normal PAH activity, with blood phenylalanine exceeding 1200 micromol/L (greater than 20 mg/dL) on unrestricted diet. Without treatment, severe intellectual disability results. Strict dietary phenylalanine restriction is required.

### Moderate PKU

Moderate PKU involves 1-5% residual PAH activity with blood phenylalanine of 600-1200 micromol/L (10-20 mg/dL). Significant cognitive risk exists without treatment, though dietary management may be somewhat less restrictive than in classic PKU.

### Mild PKU (Hyperphenylalaninemia)

Mild PKU presents with blood phenylalanine of 360-600 micromol/L (6-10 mg/dL). Cognitive risk is lower, and treatment recommendations vary, though many guidelines recommend treatment if phenylalanine exceeds 360 micromol/L.

### BH4-Deficient Hyperphenylalaninemia

Defects in BH4 synthesis (GTPCH, PTPS) or recycling (DHPR) account for 1-3% of hyperphenylalaninemia cases and must be ruled out in every newborn with elevated phenylalanine. BH4 deficiency causes progressive neurological deterioration even with phenylalanine restriction because BH4 is also essential for tyrosine hydroxylase and tryptophan hydroxylase (neurotransmitter synthesis). Treatment requires BH4 supplementation plus neurotransmitter precursors (L-DOPA, 5-hydroxytryptophan) and folinic acid for DHPR deficiency. Screening involves urine pterin analysis and DHPR activity in DBS.

| PKU Classification | Residual PAH Activity | Blood Phe (Unrestricted Diet) | Severity | Treatment |
|---|---|---|---|---|
| Classic PKU | <1% | >1200 µmol/L (>20 mg/dL) | Severe ID if untreated | Strict Phe-restricted diet; medical formula |
| Moderate PKU | 1–5% | 600–1200 µmol/L (10–20 mg/dL) | Significant cognitive risk | Phe-restricted diet (somewhat less restrictive) |
| Mild PKU (HPA) | >5% | 360–600 µmol/L (6–10 mg/dL) | Lower cognitive risk | Treatment if Phe >360 µmol/L per guidelines |
| BH4-deficient HPA | Variable PAH; cofactor deficiency | Variable | Progressive neurological deterioration | BH4 + L-DOPA + 5-HTP ± folinic acid |

## Molecular Genetics

### PAH Gene

The PAH gene is located on chromosome 12q23.2 with over 1,100 pathogenic variants identified in the PAHvdb database. Most patients are compound heterozygotes carrying two different mutations. Genotype-phenotype correlation is moderate, allowing prediction of metabolic phenotype (classic versus mild) based on the residual activity of the less severe allele. Common mutations vary by population: IVS12+1G>A (severe, Northern Europe), R408W (severe, Eastern Europe), I65T (mild, many populations), and R261Q (moderate, Southern Europe).

### BH4 Responsiveness and Genotype

Approximately 25-50% of PKU patients show some response to pharmacologic doses of BH4 (sapropterin). BH4 responsiveness correlates with residual PAH enzyme activity, with mild/moderate genotypes more likely to respond. Genotype can predict BH4 responsiveness and guide decisions about sapropterin therapy trials.

## Newborn Screening and Diagnosis

### Screening

Phenylalanine is measured in DBS by tandem mass spectrometry, with the Phe/Tyr ratio also assessed to increase specificity. Screen-positive thresholds vary by state, typically set at phenylalanine above 120-150 micromol/L (2-2.5 mg/dL). DBS collection at 24-48 hours of life requires prior protein intake for phenylalanine to rise. False negatives are possible if collected too early or with inadequate protein intake.

### Confirmatory Testing

Confirmatory workup includes quantitative plasma amino acids (elevated Phe, elevated Phe/Tyr ratio), urine pterin analysis (neopterin, biopterin) and DBS DHPR activity to rule out BH4 deficiency, BH4 loading test (20 mg/kg BH4 with serial Phe levels; greater than 30% reduction suggests BH4 responsiveness), and PAH genotyping to confirm diagnosis, predict severity, and guide treatment.

<image>Algorithm for the diagnostic workup of elevated phenylalanine on newborn screening, including confirmatory plasma amino acids, BH4 deficiency evaluation (pterin analysis and DHPR assay), BH4 loading test, and PAH genotyping</image>

## Treatment

### Dietary Management

The phenylalanine-restricted diet is lifelong and limits natural protein intake to maintain blood phenylalanine in the target range of 120-360 micromol/L (2-6 mg/dL) for all ages per current guidelines. Medical formula (Phe-free amino acid supplements) provides protein, vitamins, and minerals without phenylalanine. Low-protein modified foods (special breads, pastas, rice substitutes) are dietary staples. The diet is highly restrictive, excluding meat, fish, dairy, eggs, nuts, legumes, and regular bread or pasta. Monitoring involves blood phenylalanine levels 1-2 times weekly in infancy, weekly to biweekly in childhood, and at least monthly in adults. Nutritional monitoring tracks pre-albumin, essential fatty acids, and vitamins (B12, folate, iron, zinc).

### Sapropterin (Kuvan/BH4)

Synthetic BH4 is FDA-approved for BH4-responsive PKU, with response defined as 30% or greater reduction in blood phenylalanine on a controlled trial. Approximately 25-50% of patients show some response, predominantly those with mild/moderate genotypes. Responders can liberalize dietary phenylalanine intake. Dosing is 5-20 mg/kg/day with generally good tolerability.

### Pegvaliase (Palynziq)

Pegvaliase is a PEGylated recombinant phenylalanine ammonia lyase (PAL) that provides enzyme substitution therapy, converting phenylalanine to trans-cinnamic acid and ammonia. It is FDA-approved for adults with PKU and blood phenylalanine above 600 micromol/L on existing management. Administered as subcutaneous injections with dose titration over months, it carries significant adverse effects including injection site reactions (common), anaphylaxis risk (requiring a REMS program and epinephrine autoinjector), arthralgia, and immune complex-mediated reactions. For some patients it dramatically improves quality of life, though adherence is challenged by injection burden and side effects.

### Emerging Therapies

Gene therapy using AAV-mediated PAH gene delivery to the liver is in clinical trials. mRNA therapy with lipid nanoparticle-encapsulated PAH mRNA is in preclinical/early clinical stages. Phenylalanine-degrading probiotics (engineered gut bacteria expressing PAL) are also in clinical trials.

## Maternal PKU Syndrome

### Pathophysiology

Elevated maternal phenylalanine is teratogenic to the developing fetus. Phenylalanine crosses the placenta and concentrates in fetal blood at 1.5-2 times maternal levels. Fetal PAH cannot compensate for maternal hyperphenylalaninemia.

### Fetal Effects

The teratogenic effects include microcephaly (approximately 73%), intellectual disability (approximately 92%), congenital heart disease (approximately 12%), intrauterine growth restriction (approximately 40%), and facial dysmorphism. Risk correlates with maternal blood phenylalanine levels during pregnancy.

### Prevention

Prevention requires strict metabolic control (phenylalanine below 360 micromol/L) before conception and throughout pregnancy. Pre-conception counseling is essential for all women with PKU. The fetus does not have PKU (being heterozygous); damage results from exposure to high maternal phenylalanine.

<image>Infographic showing the effects of maternal PKU on the developing fetus at different blood phenylalanine levels, with the relationship between maternal Phe control and risk of microcephaly, cardiac defects, and intellectual disability</image>

## Long-Term Outcomes and Monitoring

### Neurocognitive Outcomes

Early and continuously treated individuals achieve near-normal IQ, though executive function deficits (attention, processing speed, working memory) may persist even with good phenylalanine control. White matter changes on MRI correlate with phenylalanine levels and are partially reversible with improved control. Psychiatric comorbidities include increased rates of anxiety, depression, and ADHD.

### Nutritional Complications

Bone mineral density may be reduced due to dietary restrictions and suboptimal vitamin D and calcium intake. Essential fatty acid deficiency occurs if the diet is not supplemented. Micronutrient deficiencies (iron, zinc, B12, selenium) require monitoring. Overweight and obesity are increasingly common due to high carbohydrate intake from low-protein foods.

### Transition to Adult Care

Historically many patients discontinued diet in adolescence or adulthood, but current consensus supports diet for life. Elevated phenylalanine in adulthood causes executive dysfunction, psychiatric symptoms, and white matter changes. Transition clinics and adult metabolic medicine services are essential but often lacking. Adherence decreases significantly in adolescence and adulthood.

## Clinical Pearls

Every infant with elevated phenylalanine on NBS must have BH4 deficiency ruled out (pterin analysis plus DHPR assay) because BH4 deficiency requires fundamentally different treatment including neurotransmitter precursors. Maternal PKU is preventable with strict pre-conception phenylalanine control; all women with PKU of reproductive age should receive contraception counseling and pre-conception planning. Genotype predicts metabolic severity and BH4 responsiveness, and genotyping should be performed in all newly diagnosed patients. A normal NBS does not guarantee normal phenylalanine levels, as premature infants and those with inadequate protein intake at screening may have false-negative results. Pegvaliase has transformed management for adults with uncontrolled PKU but requires careful anaphylaxis risk management. PKU is the paradigm for newborn screening: it demonstrates that early detection plus intervention prevents catastrophic outcomes, a model replicated for dozens of conditions.

## References

- Vockley J, Andersson HC, Antshel KM, et al. "Phenylalanine hydroxylase deficiency: diagnosis and management guideline." *Genetics in Medicine*. 2014;16(2):188-200.
- van Wegberg AMJ, MacDonald A, Ahring K, et al. "The complete European guidelines on phenylketonuria: diagnosis and treatment." *Orphanet Journal of Rare Diseases*. 2017;12:162.
- Thomas J, Levy H, Amato S, et al. "Pegvaliase for the treatment of phenylketonuria: results of a long-term phase 3 clinical trial program (PRISM)." *Molecular Genetics and Metabolism*. 2018;124(1):27-38.
- Koch R, Hanley W, Levy H, et al. "The Maternal Phenylketonuria International Study: 1984-2002." *Pediatrics*. 2003;112(6 Suppl):1523-1529.
- Blau N, van Spronsen FJ, Levy HL. "Phenylketonuria." *Lancet*. 2010;376(9750):1417-1427.